Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Autoimmune Diseases of the Nervous System 1Anti-N-Methyl-D-Aspartate Receptor Encephalitis 1

Interventions

Cyclophosphamide 55fludarabine 29Methotrexate 25blinatumomab 22Dexamethasone 22Cytarabine 21Vincristine 20venetoclax 18fludarabine phosphate 15Specimen Handling 15Whole-Body Irradiation 13Stem Cell Transplantation 11Biopsy 11Tacrolimus 10Prednisone 10Mycophenolic Acid 10Mercaptopurine 10Daunorubicin 10Thiotepa 9Rituximab 9Melphalan 9Immunotherapy, Adoptive 9Doxorubicin 8pegaspargase 7Magnetic Resonance Spectroscopy 7Inotuzumab Ozogamicin 7Granulocyte Colony-Stimulating Factor 7Cyclosporine 7Calcium Dobesilate 7ponatinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × ofatumumab × Clear all
NCT03136146 2026-02-17

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
42 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡